Title of article
Drug-eluting stents for diabetes mellitus: A rush to judgment? Review Article
Author/Authors
Aloke V. Finn، نويسنده , , Igor F. Palacios، نويسنده , , Adnan Kastrati، نويسنده , , Herman K. Gold، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2005
Pages
5
From page
479
To page
483
Abstract
The two pivotal U.S. trials of drug-eluting stents do not establish the principle that these stents are superior to thin-strut bare-metal stents for preventing repeat revascularization in patients with diabetes. Neither study was adequately powered to make this determination. Moreover, both studies used thick-strut stents known to have high restenosis rates as controls. Low angiographic follow-up underestimates the true target lesion revascularization rate in the Polymer-Based Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease (TAXUS-IV) trial because of the high incidence of silent ischemia in patients with diabetes. Optimal therapy for diabetic coronary disease should include a comprehensive approach directed toward metabolic normalization in addition to local stent-based therapy.
Keywords
PCI , PPAR , DES , TLR , SES , PES , Percutaneous coronary intervention , Sirolimus-eluting stent , SIRIUS , target lesion revascularization , paclitaxel-eluting stent , BMS , bare-metal stent , drug-eluting stents , ISAR-STEREO , Intracoronary Stenting and Angiographic Results-Strut Thickness Effect on Restenosis Outcomes trial , peroxisome proliferator-activated receptor , RVD , reference vessel diameter , Sirolimus-coated BX Velocity Balloon-Expandable Stent in the Treatment of Patients With De Novo Coronary Artery Lesions , TAXUS-IV , Polymer-Based Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease
Journal title
JACC (Journal of the American College of Cardiology)
Serial Year
2005
Journal title
JACC (Journal of the American College of Cardiology)
Record number
459726
Link To Document